Patents Examined by Suzanne M. Noakes
-
Patent number: 11746337Abstract: Disclosed are methods for isolating polymerase complexes from a mixture of polymerase complex components. The polymerase complexes can comprise a nanopore to provide isolated nanopore sequencing complexes. The methods relate to the positive and negative isolation of the polymerase complexes and/or nanopore sequencing complexes. Also disclosed is a nucleic acid adaptor for isolating active polymerase complexes, polymerase complexes comprising the nucleic acid adaptor, and methods for isolating active polymerase complexes using the nucleic acid adaptor.Type: GrantFiled: May 11, 2020Date of Patent: September 5, 2023Assignee: Roche Sequencing Solutions, Inc.Inventors: Helen Franklin, Cynthia Cech, Timothy Kellogg Craig, Aruna Ayer, Kirti Dhiman, Natalie B. Chechelski Johnston, Joshua N. Mabry, Arkadiusz Bibillo, Peter Crisalli, Randall W. Davis
-
Patent number: 11746341Abstract: Proteases may include an amino acid sequence which has at least 70% sequence identity with the amino acid sequence given in SEQ ID NO:1 over its entire length and has (i) one or more first amino acid substitutions at positions corresponding to positions 3, 4, 99, 199, or combinations thereof, and (ii) one or more second amino acid substitutions at positions corresponding to positions 9, 21, 42, 44, 105, 112, 113, 131, 137, 139, 141, 145, 159, 168, 176, 177, 182, 193, 198, 204, 205, 206, 210, 212, 230, 234, 250, 253, 255, 259, 267, or combinations thereof based on the numbering according to SEQ ID NO:1, and relates to the preparation and use thereof. Proteases of this kind demonstrate very good stability with good cleaning performance.Type: GrantFiled: November 28, 2019Date of Patent: September 5, 2023Assignee: Henkel AG & Co. KGaAInventors: Christian Degering, Layla Fernandez, Sabine Griemert, Nina Mussmann, Inken Prueser, Daria Strauss, Susanne Wieland
-
Patent number: 11738056Abstract: Provided herein are methods and compositions comprising a bacterium or a metabolite thereof for enhancing mitochondrial and/or peroxisomal function.Type: GrantFiled: March 9, 2021Date of Patent: August 29, 2023Assignee: THE GENERAL HOSPITAL CORPORATIONInventors: Gary Ruvkun, J. Amaranath Govindan, Elamparithi Jayamani
-
Patent number: 11739358Abstract: The present invention relates to an enzyme-catalyzed process for producing UDP-galactose from low-cost substrates uridine monophosphate and D-galactose in a single reaction mixture. The process can be operated (semi)continuously or in batch mode. The process can be extended to uridine as starting material instead of uridine monophosphate. Further, the process can be adapted to produce galactosylated molecules and biomolecules including saccharides, proteins, peptides, glycoproteins or glycopeptides, particularly human milk oligosaccharides (HMO) and (monoclonal) antibodies.Type: GrantFiled: September 30, 2020Date of Patent: August 29, 2023Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Reza Mahour, Thomas F. T. Rexer
-
Patent number: 11739032Abstract: Disclosed herein are methods of increasing nitrogen fixation in a non-leguminous plant. The methods can comprise exposing the plant to a plurality of bacteria. Each member of the plurality comprises one or more genetic variations introduced into one or more genes or non-coding polynucleotides of the bacteria's nitrogen fixation or assimilation genetic regulatory network, such that the bacteria are capable of fixing atmospheric nitrogen in the presence of exogenous nitrogen. The bacteria are not intergeneric microorganisms. Additionally, the bacteria, in planta, produce 1% or more of the fixed nitrogen in the plant.Type: GrantFiled: January 13, 2021Date of Patent: August 29, 2023Assignee: Pivot Bio, Inc.Inventors: Karsten Temme, Alvin Tamsir, Sarah Bloch, Rosemary Clark, Emily Tung
-
Patent number: 11739338Abstract: Acetate is a potent microbial inhibitor which can affect the performance of yeast in ethanolic fermentation. The present disclosure provides a recombinant microbial host cell having (i) a first genetic modification for increasing the activity of one or more proteins that function in a first metabolic pathway to convert acetate into an alcohol in the microbial host cell; (ii) a second genetic modification for increasing the activity of one or more proteins that function in a second metabolic pathway to import glycerol in the recombinant microbial host cell (iii) a third genetic modification for increasing the activity of one or more proteins that function in a third metabolic pathway to convert a C5 carbohydrate into ethanol in the microbial host cell. The recombinant microbial host cell comprises and natively expresses native proteins that function in a fourth native metabolic pathway to produce glycerol in the microbial host cell.Type: GrantFiled: September 18, 2018Date of Patent: August 29, 2023Assignee: LALLEMAND HUNGARY LIQUIDITY MANAGEMENT LLCInventors: Brooks Henningsen, Sean Covalla, Rintze Zelle, Allan Froehlich
-
Patent number: 11739336Abstract: Provided are mutants PHY1, PHY4 and PHY5 of a wild-type phytase APPA. After being treated for 10 min at 80° C., the residual enzyme activities of the mutants PHY1, PHY4 and PHY5 are respectively higher by 33.85%, 53.11% and 75.86% compared with that of APPA-M; after being treated for 5 min at 85° C., the residual enzyme activities of the mutants PHY1, PHY4 and PHY5 are respectively higher by 14.89%, 28.45% and 44.94% compared with that of APPA-M, and the heat resistance of these mutants is significantly higher than that of APPA-M.Type: GrantFiled: July 28, 2021Date of Patent: August 29, 2023Assignee: Qingdao Vland Biotech Group Co., Ltd.Inventors: Xiuxiu Wu, Huaming Wang
-
Patent number: 11730730Abstract: Provided herein are small molecule-inhibitors of site-specific O-glycosylation and the identification of such using cell-based fluorescent biosensors. Also provided herein are methods of treating kidney disease and cancer, such as breast cancer.Type: GrantFiled: May 26, 2021Date of Patent: August 22, 2023Assignee: Carnegie Mellon UniversityInventors: Adam D. Linstedt, Lina Song, Collin Bachert
-
Patent number: 11732274Abstract: The instant specification provides for evolved base editors which overcome deficiencies of those in art (including increased efficiency and/or decreased requirement for specific sequence-context at an editing site) and which are obtained a result of a phage-assisted continuous evolution (PACE) system. In particular, the instant specification provides for evolved cytidine base editors (e.g., based on APOBEC1, CDA, or AID cytidine deaminase domains) which overcome deficiencies of those in art (including increased efficiency and/or decreased requirement for specific sequence-context at an editing site) and which are obtained a result of a phage-assisted continuous evolution (PACE) system.Type: GrantFiled: July 27, 2018Date of Patent: August 22, 2023Assignees: President and Fellows of Harvard College, The Broad Institute, Inc.Inventors: David R. Liu, Ben Thuronyi, Christopher Gerard Wilson
-
Patent number: 11725196Abstract: The present disclosure relates to compositions, kits, and methods of making RNA vaccines having an appropriate cap structure. Systems, apparatus, compositions, and/or methods may include and/or use, in some embodiments, non-naturally occurring single-chain RNA capping enzymes. In some embodiments, an RNA capping enzyme may include an FCE variant having (a) an amino acid sequence at least 90% identical to positions 1 to 878 of SEQ ID NO: 1, and/or (b) one or more substitutions relative to SEQ ID NO: 1 at a position selected from positions corresponding to positions 215, 337, 572, 648, and 833 (e.g., a position selected from positions corresponding to position 215, 337, and 572) of SEQ ID NO: 1.Type: GrantFiled: July 16, 2021Date of Patent: August 15, 2023Assignee: New England Biolabs, Inc.Inventors: Mehul Ganatra, Siu-hong Chan, Christopher H. Taron, G. B. Robb
-
Patent number: 11713453Abstract: The invention concerns fusion proteins, wherein two endoglycosidases are fused, possibly via a linker. The fusion enzymes according to the invention have structure (1): EndoX-(L)p-EndoY (1), wherein EndoX is an endoglycosidase, EndoY is an endoglycosidase distinct from EndoX, L is a linker and p is 0 or 1. Such fusion enzymes capable of trimming glycoproteins comprising at least two distinct glycoforms in a single step. The invention further concerns the use of the fusion enzyme according to the invention for trimming glycoproteins. In another aspect, the invention relates to the process of production of the fusion enzyme. In a further aspect, the inventions concerns a process for trimming glycoproteins, comprising trimming the glycoprotein with a fusion enzyme according to the invention, to obtain a trimmed glycoprotein.Type: GrantFiled: December 7, 2020Date of Patent: August 1, 2023Assignee: SYNAFFIX B.V.Inventors: Remon Van Geel, Maria Antonia Wijdeven, Inge Catharina Josephina Hurkmans, Floris Louis Van Delft, Sander Sebastiaan Van Berkel
-
Patent number: 11713452Abstract: Certain embodiments are directed to modified or variant Cas9 proteins, and/or methods of using the same.Type: GrantFiled: September 10, 2018Date of Patent: August 1, 2023Assignee: UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTERInventors: Jin Liu, Zhicheng Zuo, Yu-Chieh Wang
-
Patent number: 11708593Abstract: The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3?-phosphoadenosine 5?-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.Type: GrantFiled: September 21, 2022Date of Patent: July 25, 2023Assignee: OPTIMVIA, LLCInventors: Daniel H. Lajiness, Tarsis Gesteira Ferreira
-
Patent number: 11702644Abstract: Disclosed herein include methods and compositions for incorporating an effector gene into the genome of a cell. The method can comprise introducing into a cell a donor nucleic acid comprising a recognition site, a splice acceptor site, a self-cleaving peptide sequence, an effector gene, and an optional transcript stabilization element. The donor nucleic acid can be incorporated into the intron of a target gene differentially expressed in a unique cell type and/or in a cell during a unique cell state via non-homologous end joining (NHEJ)-dependent DNA repair. There are also provided, in some embodiments, methods and compositions for treating a disease or disorder in a subject.Type: GrantFiled: April 9, 2020Date of Patent: July 18, 2023Assignee: California Institute of TechnologyInventors: Yuki Oka, Allan-Hermann Pool
-
Patent number: 11702641Abstract: The purpose of the present invention is to provide a steviol glycoside hexose transferase, and a method for producing a steviol glycoside that contains glucose and/or rhamnose using said enzyme. The present invention provides a steviol glycoside hexose transferase, and a method for producing a steviol glycoside that contains glucose and/or rhamnose using said enzyme. The present invention also provides a transformant into which a steviol glycoside hexose transferase gene has been introduced, and a method for preparing said transformant.Type: GrantFiled: December 26, 2017Date of Patent: July 18, 2023Assignee: SUNTORY HOLDINGS LIMITEDInventors: Eiichiro Ono, Misa Ochiai, Kazunari Iwaki, Tadayoshi Hirai
-
Patent number: 11702456Abstract: An expression system and process for the production of Diphtheria toxin polypeptides or mutated forms thereof, such as the toxoid CRM197 polypeptide, in genetically-modified E. coli with high yield is described. The system and process is based on the uncoupling of biomass growth from recombinant protein induction, i.e. using an inducer of protein production that cannot be used as a carbon source for growth by the bacteria. The use of specific components and conditions that improve protein yields are also described.Type: GrantFiled: August 16, 2018Date of Patent: July 18, 2023Assignee: National Research Council of CanadaInventors: Luke Masson, Melanie Arbour, Marie-Anne Gauriat
-
Patent number: 11702686Abstract: The present disclosure describes compositions of matter comprising a ribonucleoprotein complex comprising a nucleic acid-guided nuclease and a guide RNA, and further comprising and a blocking nucleic acid molecule represented by Formula I, wherein Formula I in the 5?-to-3? direction comprises: A-(B-L)J-C-M-T-D; wherein A is 0-15 nucleotides in length; B is 4-12 nucleotides in length; L is 3-25 nucleotides in length; J is an integer between 1 and 10; C is 4-15 nucleotides in length; M is 1-25 nucleotides in length or is absent, wherein if M is absent then A-(B-L)J-C and T-D are separate nucleic acid strands; T is 17-135 nucleotides in length and comprises at least 50% sequence complementarity to B and C; D is 0-10 nucleotides in length and comprises at least 50% sequence complementarity to A; and wherein the blocking nucleic acid molecule comprises a sequence complementary to a gRNA.Type: GrantFiled: February 6, 2023Date of Patent: July 18, 2023Assignees: LabSimply, Inc., The Board of Trustees of the University of IllinoisInventors: Anurup Ganguli, Ariana Mostafa, Jacob Berger, Ashish Pandey, Rashid Bashir
-
Patent number: 11702643Abstract: The invention relates to the field of genetic engineering. In particular, the present invention relates to a novel eukaryotic genome editing system and method. More specifically, the present invention relates to a CRISPR-Cpf1 system capable of efficiently editing a genome of a eukaryotic cell and the use thereof.Type: GrantFiled: April 10, 2018Date of Patent: July 18, 2023Assignee: INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCESInventors: Wei Li, Qi Zhou, Fei Teng
-
Patent number: 11697808Abstract: Engineered Streptococcus canis Cas9 (ScCas9) variants include an ScCas9 protein with its PID being the PID amino acid composition of Streptococcus pyogenes Cas9 (SpCas9)-NG, an ScCas9 protein having a threonine-to-lysine substitution mutation at position 1227 in its amino acid sequence (Sc+), and an ScCas9 protein having a threonine-to-lysine substitution mutation at position 1227 and a substitution of residues ADKKLRKRSGKLATE [SEQ ID No. 4] in position 365-379 in the ScCas9 open reading frame (Sc++). Also included are CRISPR-associated DNA endonucleases with a PAM specificity of 5?-NG-3? or 5?-NNG-3? and a method of altering expression of a gene product by utilizing the engineered ScCas9 variants.Type: GrantFiled: June 30, 2022Date of Patent: July 11, 2023Assignee: Massachusetts Institute of TechnologyInventors: Pranam Chatterjee, Noah Michael Jakimo, Joseph M. Jacobson
-
Patent number: 11697818Abstract: The present invention provides a pyruvate-responsive biosensor and a construction method and use thereof. In the present invention, pyruvate-responsive biosensors with different dynamic ranges are successfully constructed by optimizing the PdhR binding sequence inserted on the P43 promoter and optimizing the insertion site, wherein the minimum increase in dynamic range is by 0.6 time, and the maximum increase is by 30.7 times. The pyruvate-responsive biosensors are useful in the precise control of the expression of each gene in the cell. Since pyruvate is a key metabolite of central carbon in the cells, these biosensors are capable of dynamically regulating the expression level of intracellular genes according to changes in the content of pyruvate in the cells, thereby achieving the dynamic control of intracellular metabolic flux. The pyruvate biosensor obtained in the present invention has a good specificity, and a response range to pyruvate of 10-35 nmol/g DCW.Type: GrantFiled: December 23, 2020Date of Patent: July 11, 2023Assignee: JIANGNAN UNIVERSITYInventors: Long Liu, Jian Chen, Xueqin Lv, Guocheng Du, Jianghua Li, Xianhao Xu